Germline Mutations in the PTEN/MMAC1 Gene in Patients With Cowden Disease

• Published in: Human molecular genetics Vol. 6; no. 8; pp. 1383 - 1387
• Main Authors: Nelen, Marcel R., van Staveren, Wilma C. G., Peeters, Els A. J., Ben Hassel, Mohammed, Gorlin, Robert J., Hamm, Henning, Lindboe, Christian F., Fryns, Jean-Pierre, Sijmons, Rolf H., Woods, D. Geoffrey, Mariman, Edwin C. M., Padberg, George W., Kremer, Hannie
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.08.1997
• Subjects: Adult; Biological and medical sciences; Chromosome Mapping; Chromosomes, Human, Pair 10; Dermatology; DNA Mutational Analysis; Female; Genes, Tumor Suppressor; Germ-Line Mutation; Hamartoma Syndrome, Multiple - genetics; Humans; Male; Medical sciences; Pedigree; Phosphoric Monoester Hydrolases; Protein Tyrosine Phosphatases - genetics; PTEN Phosphohydrolase; Tumor Suppressor Proteins; Tumors of the skin and soft tissue. Premalignant lesions; Genetic mapping; Human; Skin disease; Enzyme; Family study; Phosphoprotein phosphatase; Phosphoric monoester hydrolases; Esterases; Chromosome C10; Hamartoma; Genetic disease; Cowden syndrome; Hydrolases; Tumor; Genetics; Mutation; Tumor suppressor gene
• ISSN: 0964-6906; 1460-2083; 1460-2083
• DOI: 10.1093/hmg/6.8.1383

Cowden disease, also known as multiple hamartoma syndrome, is an autosomal dominant cancer syndrome with a high risk of breast and thyroid cancer. The gene involved has been localized to chromosome 10q22–23. Recently, the tumour suppressor gene PTEN/MMAC1, encoding a putative protein tyrosine or dual-specificity phosphatase, was cloned from that region and three mutations were detected in patients with Cowden disease. We confirmed that the PTEN/MMAC1 gene is indeed the gene for Cowden disease by a refined localization of the gene to the interval between D10S1761 and D10S541, which contains the PTEN/MMAC1 gene and by mutation analysis in eight unrelated familial and 11 sporadic patients with Cowden disease. Eight different mutations were detected in various regions of the PTEN/MMAC1 gene. One mutation was detected twice. All detected changes in the gene can be predicted to have a very deleterious effect on the putative protein. Five of the nine patients have a mutation in exon 5 coding for the putative active site and flanking amino acids. Evaluation of the clinical data of the patients in which a mutation could be detected gives no clear indications for a correlation between the genotype and phenotype. In 10 patients no mutation could be detected so far. In support of the linkage data, no evidence has emerged from the phenotype of these patients suggestive for genetic heterogeneity.